The EUFOREA pocket guide for chronic rhinosinusitis*


1 KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Allergy and Clinical Immunology Research Group, Leuven, Belgium
2 University Hospitals Leuven, Department of Otorhinolaryngology, Leuven, Belgium
3 University Hospital Ghent, Department of Otorhinolaryngology, Laboratory of Upper Airways Research, Ghent, Belgium
4 Department of otorhinolaryngology and head/neck surgery, Amsterdam University Medical Centres, location AMC, University of Amsterdam, Amsterdam, The Netherlands
5 Rhinology and Skull Base, Department of Otorhinolaryngology, Hospital Clinic, Universidad de Barcelona, Centro Médico Teknon, Barcelona, Spain
6 The University of Chicago Medicine, Chicago, IL, United States
7 Dept of Respiratory Medicine and Allergology, Skane University Hospital, Lund, Sweden
8 Division of Rhinology, Allergy, and Endoscopic Skull Base Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
9 The university of Queensland Centra for Clinical Research, Herston, Australia
10 Royal Brisbane and Women's Hospital, Brisbane, Australia
11 Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, USA
12 Ist Department of O.RL, Head and Neck Surgery, Aristotle University, AHEPA Hospital, Thessaloniki, Greece
13 Department of Otolaryngology Head and Neck Surgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università CattolicaSacri Cuore, Rome, Italy
14 Department of Otolaryngology-Head and Neck Surgery, Université de Montréal, Montréal, Canada
15 Department Clinical Pharmacy and Pharmacology, University Groningen, University Medical Center Groningen, Groningen, the Netherlands
16 Department of Surgery, The University of Auckland, New Zealand
17 Royal National Ear, Nose and Throat and Eastman Dental Hospitals, London, United Kingdom
18 Department of Otolaryngology and Head and Neck Surgery at Eastern Virginia Medical School, Norfolk, Virginia, USA
19 Rhinology and Skull Base, Applied medical research Center, University of New South Wales, Sydney, Australia
20 Faculty of medicine and health sciences, Macquarie University, Sydney, Australia
21 Ear, Nose and Throat Department, Guys and St. Thomas Hospital, London, United Kingdom
22 Department of Otolaryngology, Head and Neck Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
23 Division of Allergy-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
24 Hopitaux Universitaires de Genève, Genève, Genève, Switzerland
25 Department of Head and Neck Surgery, University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA, USA
26 Brigham and Women's Hospital, Harvard Medical School, Department of Surgery, Division of Otolaryngology—Head and Neck Surgery, Section of Rhinology and Skull Base Surgery, Boston, MA, USA
27 Rhinology Center Munich and ENT-Clinic, Munich, Germany
28 Royal National Throat, Nose and Ear Hospital, UCLH, London, UK
29 Department of Otorhinolaryngology, hospital clinic Barcelona, Spain

*Received for publication: August 31, 2022
Accepted: November 28, 2022
Dear Editor:

Chronic rhinosinusitis (CRS) is known to affect around 5% of the total population, with major impact on the quality of life of those severely affected. Despite a substantial burden on individuals, society and health economies, CRS often remains under-diagnosed, under-estimated and under-treated. International guidelines like the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) and the International Consensus statement on Allergy and Rhinology: Rhinosinusitis 2021 (ICAR) offer physicians insight into the recommended treatment options for CRS, with an overview of effective strategies and guidance of diagnosis and care throughout the disease journey of CRS. However, barriers to access to appropriate diagnosis and effective treatment remain at patient, pharmacist and physician levels, including inability to recognize CRS and diagnose it, inappropriate CRS medication prescription/use, poor concordance with CRS treatment recommendations and/or lack of awareness of newly available options for CRS care. Of note, endoscopic sinus surgery and oral corticosteroids (OCS) do not always result in full disease control, with the need of referral to tertiary care. For the evaluation of the severity of disease, and follow-up of treatment outcomes, the visual analogue scale (VAS) has been introduced as a simple tool, mainly in the context of e-health for disease monitoring and clinical trials. However, guidelines based solely on VAS may not reflect the needs of physicians and patients in real-life, since VAS scores are not routinely used in everyday practice and may not capture the clinical phenotypes. In addition to VAS scores, Sino-Nasal Outcome test (SNOT)-22 scores may be more informative given the evaluation of different sinonasal and overall symptoms reflecting the burden of disease, and the well-known scores in the general population as well as in those with severe CRSwNP having been included in all surgery and biological trials in recent years.

Building further on the success of the pocket guides for adult and paediatric allergic rhinitis, the European Forum for Research & Education in Allergy & Airway Diseases (EUFOREA) in collaboration with global key opinion leaders in the field of chronic inflammatory airways disease, has developed a CRS pocket guide with a new treatment algorithm with the following aims: to expedite access to CRS diagnosis and treatment, to simplify clinical care pathways of CRS, and to facilitate coordinated care amongst the stakeholders involved in CRS care. The algorithm is based on the EPOS2020 and ICAR-Rhinosinusitis 2021 documents, and designed for real-life use. Given the clear messages on key diagnostic actions and simplicity of the CRS algorithm, the EUFOREA pocket guide aims at improving CRS knowledge amongst all stakeholders involved in CRS care and streamlining the transition of patients between self-, pharmacy-, GP- and specialist-care, facilitating more coordinated care. The EUFOREA pocket guide also includes a diagnostic checklist when assessing CRS patients including a list of symptoms suggestive and less suggestive of CRS, questions on suspected comorbid asthma, and instructions on how to use the VAS for CRS. The diagnosis of smell dysfunction and nasal congestion or obstruction require specific diagnostic actions beyond history by health care providers (Figure 1). In addition a list of suggested indications is provided for referral of specific CRS patients to specific colleagues, reflecting the heterogeneity of health care providers involved in CRS care. It makes sense to adopt multi-disciplinary assessments and management for specific patients suffering from como-
The CRS pocket guide is presented as 5 easy steps: (i) diagnosis, (ii) classification of patients, (iii) definition of therapy, (iv) selection of product, and (v) activation of treatment plan, and with pro-active follow-up of patients. As an overall consideration (Figure 2), patients should be educated on the disease, treatment adherence and avoidance of external triggers, with nasal rinsing and nasal corticosteroids being the mainstay of care. In case of failure of the basics, referred to as step 1 in the algorithm, a firm diagnosis is recommended at specialist level with the consideration of OCS or Endoscopic Sinus Surgery (ESS). In case of failure of step 2 treatment and/or uncontrolled severe CRS, endotyping is recommended at specialist level, including different options for the Type 1 and Type 2 endotypes of CRS. Interestingly, the key pillars of care for severe uncontrolled CRS, i.e., OCS, ESS and biologics all have pros and cons that need to be considered at the time of implementation. At any time in the disease journey, there are red flags that warrant immediate referral and emergency care, as listed in the treatment algorithm (Figure 2).

The CRS pocket guide is available on the EUFOREA (www.euforea.eu) and Rhinology (https://www.rhinologyjournal.com) website, and easy-to-use in everyday clinical practice for any care provider as it is concise, patient-centered, and captures every single patient who attends the outpatient clinic of any care provider. Upon the suggestion of the Patient Advisory Board of EUFOREA, a patient version will appear in 2023 on the EUFOREA website.

Acknowledgements
None.

Authorship contribution
All authors contributed to the development and finetuning of the treatment algorithm and the pocket guide.

Conflict of interest
P. Hellings: lecture fees and/or participation at expert board meetings of ALK, Stallergenes, Mylan, Novartis, GSK and Sanofi.
Figure 2. EUFORIA CRS pocket guide treatment algorithm. AB: Antibiotics; EUFORIA: European Forum for Research & Education in Allergy & Airway Diseases; VAS: visual analogue scale.

Regeneron Pharmaceuticals Inc., Sanofi, and NOUCOR/Uriach Group – speakers’ bureau, advisory board member, or research grants. C. Philpott, E. Prokopakis: No conflict of interest to report. S. Reitsma: has acted as consultant for Sanofi-Genzyme, GSK and Novartis. D. Ryan, S. Salmi: No conflict of interest to report. G. Scadding: chaired the BSACI AR guidelines, has given paid lectures for and an education programme for EUFOREA. She also chairs the EAACI Ethics Committee, the independent data monitoring committee for an ALK allergen immunotherapy trial and the Rhinology and Laryngology Research Fund and has given lectures for and/or advised ALK, Bayer GSK, Mylan, Stallergenes. R.J. Schlosser: Consultant for: Stryker, Medtronic, Optinose, Healthy Humming, Cyano. A. Steinsvik, P.V. Tomazic, E. Van Staeyen: No conflict of interest to report. T. Van Zele: Is a consultant for Medtronic. O. Vandeveken, A-S Viskens: No conflict of interest to report. M. Wagenmann: Has received grants form ALK-Abello, GSK, regeneron, AstraZeneca, Novartis, Sanofi, Takeda in the past 36 months. Consultant with ALK-Abello, GSK, AstraZeneca, Novartis, Sanofi, Genzyme, Stallergenes. Has received payment or honoraria for lectures/presentations from ALK-Abello, AstraZeneca, Genzyme, GSK, LETI Pharma, Allergopharma, Bencard Allergie, Infectopharm, Novartis and Stallergenes. D. Conti: No conflict of interest to report.

**Funding**

Funding was provided via an unrestricted grant to EUFOREA by Sanofi Genzyme and Regeneron.

**References**


---

**Prof Dr Peter W Hellings**

Department of Otorhinolaryngology

University Hospitals Leuven

Leuven

Belgium

E-mail: Peter.Hellings@uzleuven.be
What is Chronic Rhinosinusitis (CRS)?

Chronic rhinosinusitis is an inflammation of the inner lining of the nose and paranasal sinuses for over 3 months, giving rise to 2 or more (sino)nasal symptoms, with negative impact on patients’ quality of life and high socio-economic burden.

CRS affects around 5% of the total European adult population, and is associated with increased risk of developing asthma.

What should the physician do?

- Ask about symptoms suggestive for CRS, medical history of the patient and any medication being taken
- Define the severity of disease on VAS or SNOT-22 scale
- Perform anterior rhinoscopy (all) and nasal endoscopy (ENT)
- Ask about history of allergies, asthma, atopic dermatitis and aspirin sensitivity
- Confirm suspicion of allergy by skin prick test or serum IgE
- Confirm suspicion of asthma with lung function tests

When to suspect asthma/chronic bronchitis?

Questions to your patient

☐ Have you had an episode or recurrent episodes of wheezing?
☐ Do you have a troublesome cough, especially at night/during awakening/exercise?
☐ Do you cough or wheeze after exercise?
☐ Do you produce sputum every day?
☐ Do you experience extended common cold/laryngitis/bronchitis?
☐ Does your chest feel tight or do you feel impaired breathing out?

If YES to any question: your patient should be evaluated by pulmonary function tests (PFTs) and referral to a chest physician advised.
Symptoms suggestive of CRS

- Nasal congestion / obstruction
- Nasal secretions (rhinorrhoea and/or post-nasal drip)
- Smell dysfunction (hyposmia or anosmia)
- Facial pain / headache

Symptoms less suggestive of CRS

- Unilateral symptoms
- Nose bleeding
- Sneezing
- Watery rhinorrhoea
- Runny nose at night
- Itchy nose and/or conjunctiva

How to apply the visual analogue scale (VAS)?

Ask your patient to mark on the horizontal line of 10 cm how bothersome his/her symptoms are. The ends of the horizontal line are defined as the extreme limits of the burden of disease. VAS has been validated for use on smartphones. VAS-score is categorised in mild (0-3 cm), moderate (>3-7 cm), and severe (>7-10 cm).


**Diagnosis of Smell Dysfunction**

**History of smell loss:**
- hyposmia or anosmia or parosmia
- uni/bilateral, onset, duration, progress, association with taste dysfunction
- exclude acute causes of olfactory dysfunction such as post-viral e.g. COVID infection

**ENT specialist:** nasal endoscopy and smell testing

### Value of NASAL ENDOSCOPY

- full evaluation of endonasal status: anatomy, secretions, mucosa, ostiomeatal complex and nasopharynx, specific pathology e.g. nasal polyps
- exclusion of other sinonasal conditions (e.g. neoplasm)

→ Ideal for **diagnosis** and **follow-up** of CRS care, including NP scoring

### When to consider a CT scan?

**Diagnostic purpose** in case of:
- suspicion of CRS in absence of nasal endoscopy
- discrepancy of symptoms and nasal endoscopy
- suspicion of benign / malignant lesion (unilateral and/or progressive symptoms)
- suspicion of orbital or intracranial complicatons
- pre-operative setting

→ **NOT** for follow-up of therapy or routine diagnosis of CRS
Diagnosis of **Nasal Obstruction**

History of nasal obstruction: uni/bilateral, duration, progress, continuous vs intermittent, VAS score

Clinical exam: inspection in rest and during inspiration, anterior rhinoscopy, nasal tip support and nasal valve function

**ENT specialist:** nasal flow testing: peak nasal inspiratory flow, anterior rhinometry and/or acoustic rhinometry, nasal endoscopy

---

**When to refer to a COLLEAGUE?**

Specialist in:

- **ENT** → persistent CRS symptoms despite first-line care
- **Rhinology / Sinus surgery** → persistent CRS symptoms despite second-line care
- **Pulmonology** → comorbid asthma, COPD or aspirin/NSAID intolerance
- **Immunodeficiencies / Allergology** → suspicion of immunodeficiencies or need for AIT
- **Dermatology** → comorbid AD
- **Ophthalmology** → orbital pain or (unilat/bilat) ocular symptoms
- **Neurology** → headache that cannot be explained by CRS / CT scan findings
- **Odontontology** → comorbid periodontitis, temporomandibular joint dysfunction or biting disorders
- **Psychiatry** → functional disorders, psychiatric disorders
- **General practitioner** → work-related disorders, coordination of the treatment and related diseases
How to use the CRS pocket guide in 5 steps

1. Diagnose CRS
   - History
   - Nasal endoscopy +/- CT scan
   - Diagnosis of comorbidities

2. Classify patient
   - Symptom(s)
   - Treatment response in case of historic treatment

3. Define therapy
   - Patient education
   - Therapeutic plan including medical approach
   - Patient partnership

4. Select therapeutic strategy

5. Finetune treatment plan
   Don’t forget about the comorbidities
3. Define therapy
- Patient education
- Therapeutic plan including medical approach
- Patient partnership

4. Select therapeutic strategy
- Lifestyle
- Pharmacotherapy
- Surgical technique

5. Activate treatment
- Education on expected outcomes
- Personalised follow-up

2. Reclassify patient

3. Redefine diagnosis and elaborate personalised treatment plan

6. Patient follow up
Personalized treatment based on
- treatment response
- long-term plan
- patient needs
**CRS Clinical Presentation**

**Step 1**
- 2 or more symptoms suggestive of CRS for > 3 months
  - Nasal congestion
  - Nasal secretions
  - Smell dysfunction
  - Facial pain / headache

**Step 2**
- Failure of previous treatment attempts (Step 1)
  - OR
  - Severe CRS

**Step 3**
- Failure of previous treatment attempts (Step 2)
  - OR
  - Uncontrolled severe CRS

---

**First Line Care**

*Education* patient about chronicity of disease, need for optimal adherence and avoidance of infectious, occupational, and environmental triggers e.g. by wearing a mask

At every stage give basic maintenance therapy:
- Saline rinses and/or nasal corticosteroid spray or drops

---

**Basic maintenance therapy:**
- saline rinses
- and/or nasal corticosteroid spray or drops

---

**Referral to secondary care**
- Diagnosis of CRS (incl. Nasal Endoscopy or CT)
- Screening for comorbidities (and treatment if necessary)

---

**Referral to tertiary care**
- Endotyping by nasal endoscopy, blood tests and/or histology
- Diagnosis + specific therapy of secondary CRS
- Criteria for biologicals by EUFOREA

---

**Comorbid asthma / AD / allergies**

*Red flags:* Periorbital oedema, displaced globe, double vision, ophthalmoplegia, reduced visual acuity, severe headache, frontal swelling, signs of sepsis, signs of meningitis, neurological signs, unilateral symptoms, bleeding, crusting, cacosmia
PATIENT PARTICIPATION IN TREATMENT PLAN

TERTIARY CARE
Rhinologist/Pulmonologist

Explain chronicity of disease, need for optimal adherence and avoidance of infectious, occupational, and environmental triggers e.g. by wearing a mask.

**Maintenance therapy:** Saline rinses and/or nasal corticosteroid spray or drops.

---

SECONDARY CARE
ENT - specialist/Allergologist

**Diagnosis of CRS** (incl. Nasal Endoscopy or CT)

**Screening for comorbidities** (and treatment if necessary)

**Endotyping** by nasal endoscopy, blood tests and/or histology

**Diagnosis + specific therapy of secondary CRS** (Ig deficiency, vasculitis)

**Criteria for biologicals by EUFOREA**

3-6 months:
- VAS ≥ 5
- SNOT ≥ 40

**Basic maintenance therapy** (step 1)

+ Oral corticosteroids and/or antibiotics

if no improvement

**ESS (Endoscopic Sinus Surgery)**

---

> Treatment of co-morbidities

- Periorbital oedema
- Displaced globe
- Double vision
- Ophthalmoplegia
- Reduced visual acuity
- Severe headache
- Frontal swelling
- Signs of sepsis
- Signs of meningitis
- Neurological signs
- Unilateral symptoms
- Bleeding
- Crusting
- Cacosmia

**Early referral in case of any red flags**!

---

**Basic maintenance therapy** (step 1)

Type 1
- long-term AB
- xylitol
- steroid eluting implants
- revision surgery

Type 2
- biologics
- aspirin desensitization in case of N-ERD
- revision surgery

---

3 months:
- VAS ≥ 5

**Early referral in case of any red flags**!
Sinus Surgery (primary / revision)

PRO
- Good outcomes
- Benefits on upper and lower airways
- Better delivery of post-operative intranasal therapy

CON
- Delicate surgery under general (or local) anaesthesia
- Post-operative healing may take several months
- Long-term medical care and post-operative follow-up needed in most patients

Oral Corticosteroids

PRO
- Rapid and major effect on CRS symptoms and severity
- Effective on CRS and comorbidities
- Cheap

CON
- Short-term treatment and short-lasting benefits
- Adverse events if long-term/repeated use and/or contra-indicated in some medical conditions
Biologics

PRO
• Benefits on upper and lower airways
• Long-term treatment with good outcomes
• Availability of different biologics

CON
• High cost
• Not universally available

Additional Resources:

Abbreviations

AD: Atopic dermatitis
AIT: Allergen immunotherapy
CRS: Chronic rhinosinusitis
CT: Computed tomography scan
EPOS: European Position Paper on Rhinosinusitis and Nasal Polyps
N-ERD: NSAID-exacerbated respiratory disease
NE: Nasal endoscopy
NP: Nasal polyps
NSAID: Non-steroidal anti-inflammatory drugs
PFT: Pulmonary function test
SNOT-22: Sinonasal outcome test

EUFOREA instructional videos for patients

SNOT 22 &
EPOS 2020 Criteria of Control
**Vision**

EUFOREA is an international non-profit organization forming an alliance of all stakeholders dedicated to reducing the prevalence and burden of chronic respiratory diseases through the implementation of optimal patient care via education, research and advocacy.

**Mission**

Based on its medical scientific core competency, EUFOREA offers a platform to introduce innovation and education in healthcare leading to optimal patient care.